Gestational exposure to organophosphate ester flame retardants and risk of childhood obesity in the environmental influences on child health outcomes consortium
- PMID: 39437621
- PMCID: PMC11702067
- DOI: 10.1016/j.envint.2024.109071
Gestational exposure to organophosphate ester flame retardants and risk of childhood obesity in the environmental influences on child health outcomes consortium
Abstract
Introduction: Organophosphate esters (OPEs) are increasing in use as flame retardants and plasticizers and concerns have been raised given their endocrine-disrupting activities and possible obesogenic consequences. However, longitudinal studies on gestational OPE exposure and childhood obesity are scarce. This study examined whether OPE levels in maternal urine during pregnancy were associated with the risk of childhood obesity.
Methods: OPEs were analyzed in pregnancy urine samples of 5,087 individuals from 14 studies contributing to the Environmental influences on Child Health Outcomes (ECHO) Cohort. BDCPP, DBUP/DIBP, and DPHP, detected in > 80 % of the samples, were modeled continuously and by tertiles; whereas BCPP, BBOEP, and BCETP, detected in 50-80 % of samples, were modeled categorically (not-detected, low, and high). Childhood obesity was defined by BMI z-score ≥ 95th percentile according to WHO (<2 years) and the CDC (≥2 years) metrics. Adjusted modified Poisson regression models assessed childhood obesity risk and the mixture effect was assessed using Bayesian kernel machine regression (BKMR).
Results: BMI measurements were available for 3,827 children in infancy (0.5-1.9 years), 3,921 children in early childhood (2.0-4.9 years), and 2,541 children in mid-childhood (5.0-10.0 years). Obesity was present in 16-21 % of children across age groups. In mid-childhood DBUP/DIBP second and third versus first tertiles were associated with increased obesity risk (RR 1.14; 95 % CI: 1.02, 1.28; and RR 1.11; 95 % CI: 0.97, 1.27; respectively); whereas BDCPP second and third versus first tertiles reflected an inverse association with obesity risk (RR 0.85; 95 % CI: 0.80, 0.91 and RR 0.91; 95 % CI: 0.77, 1.07; respectively). No association with obesity risk was observed for DPHP, BCPP, BBOEP, and BCETP. Directions observed were consistent with those seen in BKMR models.
Conclusions: This study identified mixed associations between gestational OPE exposure and childhood obesity. Further investigation across a comprehensive range of OPE exposures is warranted.
Keywords: Childhood obesity; Flame retardants; OPE; Pregnancy.
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures




References
MeSH terms
Substances
Grants and funding
- UH3 OD023286/OD/NIH HHS/United States
- UH3 OD023348/OD/NIH HHS/United States
- U24 OD035523/OD/NIH HHS/United States
- UH3 OD023287/OD/NIH HHS/United States
- UG3 OD035518/OD/NIH HHS/United States
- UG3 OD035529/OD/NIH HHS/United States
- UH3 OD023268/OD/NIH HHS/United States
- U2C ES026533/ES/NIEHS NIH HHS/United States
- U24 OD023382/OD/NIH HHS/United States
- UH3 OD023313/OD/NIH HHS/United States
- UH3 OD023289/OD/NIH HHS/United States
- UH3 OD023332/OD/NIH HHS/United States
- U2C ES026542/ES/NIEHS NIH HHS/United States
- UG3 OD035509/OD/NIH HHS/United States
- U2C ES026555/ES/NIEHS NIH HHS/United States
- U2C ES030857/ES/NIEHS NIH HHS/United States
- U2C ES026561/ES/NIEHS NIH HHS/United States
- P30 ES010126/ES/NIEHS NIH HHS/United States
- UH3 OD023249/OD/NIH HHS/United States
- UG3 OD035528/OD/NIH HHS/United States
- UH3 OD023389/OD/NIH HHS/United States
- UH3 OD023290/OD/NIH HHS/United States
- U2C OD023375/OD/NIH HHS/United States
- UG3 OD035544/OD/NIH HHS/United States
- U24 ES026539/ES/NIEHS NIH HHS/United States
- UH3 OD023285/OD/NIH HHS/United States
- UG3 OD035517/OD/NIH HHS/United States
- UH3 OD023344/OD/NIH HHS/United States
- UG3 OD035540/OD/NIH HHS/United States
- P30 ES036084/ES/NIEHS NIH HHS/United States
- UH3 OD023275/OD/NIH HHS/United States
- P30 ES001247/ES/NIEHS NIH HHS/United States
- UH3 OD023318/OD/NIH HHS/United States
- UG3 OD035521/OD/NIH HHS/United States
- UH3 OD023271/OD/NIH HHS/United States
- UG3 OD035508/OD/NIH HHS/United States
- UG3 OD035546/OD/NIH HHS/United States
- P30 ES005022/ES/NIEHS NIH HHS/United States
- UG3 OD035532/OD/NIH HHS/United States
- UH3 OD023282/OD/NIH HHS/United States
- UG3 OD035519/OD/NIH HHS/United States
- UH3 OD023248/OD/NIH HHS/United States
- U24 OD023319/OD/NIH HHS/United States
- R03 CA222450/CA/NCI NIH HHS/United States
- UG3 OD035543/OD/NIH HHS/United States
- U2C ES030851/ES/NIEHS NIH HHS/United States
- UH3 OD023305/OD/NIH HHS/United States
- UG3 OD035533/OD/NIH HHS/United States
- UH3 OD023253/OD/NIH HHS/United States
- UH3 OD023272/OD/NIH HHS/United States
- U2C ES030859/ES/NIEHS NIH HHS/United States
- UG3 OD035550/OD/NIH HHS/United States
- UG3 OD035537/OD/NIH HHS/United States
- UH3 OD023347/OD/NIH HHS/United States
- UH3 OD023251/OD/NIH HHS/United States
- UH3 OD023279/OD/NIH HHS/United States
- UG3 OD035542/OD/NIH HHS/United States
- UG3 OD035526/OD/NIH HHS/United States
- UH3 OD023288/OD/NIH HHS/United States
- U01 CA235507/CA/NCI NIH HHS/United States
- UH3 OD023342/OD/NIH HHS/United States
- UH3 OD023244/OD/NIH HHS/United States
- UH3 OD023320/OD/NIH HHS/United States
- UG3 OD035527/OD/NIH HHS/United States
- UG3 OD035536/OD/NIH HHS/United States
- UH3 OD023349/OD/NIH HHS/United States
- UG3 OD035513/OD/NIH HHS/United States
- UH3 OD023365/OD/NIH HHS/United States
- UH3 OD023337/OD/NIH HHS/United States
- R01 HL159701/HL/NHLBI NIH HHS/United States
- UG3 OD035516/OD/NIH HHS/United States
- UH3 OD023328/OD/NIH HHS/United States